SLU-PP-332 Peptide

In modern society with a high incidence of metabolic diseases, traditional intervention methods such as exercise and dietary control are effective, but due to factors such as patient compliance and physical conditions, it is difficult to achieve comprehensive coverage. The product, with its unique metabolic regulation mechanism, breaks the vicious circle of metabolic imbalance through "mandatory intervention", and opens up a new path for the treatment of obesity, diabetes, heart failure and other metabolic related diseases.

Precise regulation of energy metabolism "switch"

It functions as a molecular mimic of exercise, exerting its beneficial metabolic effects primarily through the activation of ERR signaling pathways. It directly modulates core energy switches, shifting systemic metabolism toward enhanced catabolism and efficient energy utilization.

Enhanced fatty acid oxidation: It strongly promotes the breakdown and combustion of fat stores. In preclinical models using diet-induced obese mice, oral administration of it significantly increased hepatic and muscular fatty acid oxidation rates by 25–50%. The body preferentially switches to using fat as the primary fuel source, reducing excessive reliance on glucose consumption, improving peripheral insulin sensitivity, and lowering fasting blood glucose and insulin levels.

Conversion of muscle fiber types: It induces a phenotypic shift in skeletal muscle fibers, promoting the formation and maintenance of oxidative type I muscle fibers. The proportion of these fatigue-resistant, high-endurance fibers increases by 35–40%. In functional tests, treated mice demonstrate significantly improved exercise performance, with prolonged running time by up to 70% and increased running distance by 45%, reflecting enhanced endurance capacity similar to chronic exercise adaptation.

Systematic reshaping of metabolic pathways

This multi-target, multi-pathway regulatory profile enables it to stabilize and smooth extreme fluctuations in metabolism at the molecular level. Instead of merely alleviating individual symptoms, it achieves holistic restoration of metabolic homeostasis, making it a highly promising intervention for a spectrum of interrelated metabolic disorders.

Mandatory Intervention and the Restoration of Metabolic Homeostasis

The term "mandatory intervention" highlights the unique pharmacological advantage of the product: it actively drives metabolic improvement without relying entirely on voluntary behavior changes. In patients with long-term metabolic disorders, the internal regulatory system often becomes desensitized or dysregulated, resulting in persistent insulin resistance, fat accumulation, energy waste, and low-grade chronic inflammation. In such a state, simple lifestyle adjustments are often insufficient to reverse the pathological process.

It acts directly on the upstream regulatory nodes of energy metabolism, forcibly reactivating the blocked ERR signaling pathway, restarting efficient mitochondrial function, and restoring the body's natural ability to burn fat and maintain glucose balance. Unlike traditional hypoglycemic or lipid-lowering drugs that only act on a single indicator, it does not temporarily cover up symptoms, but stabilizes the entire metabolic system from the source, smoothing sharp fluctuations in blood glucose, lipid, and energy supply.

Red swelling and pain at the injection site

In experimental studies and early clinical observations using it for injection administration, redness, swelling, and pain at the injection site were the most common local adverse reactions. Research data shows that approximately 30% -40% of individuals in experimental animals (such as mice and rats) and a small number of volunteers who receive injections of this peptide exhibit varying degrees of redness and swelling at the injection site. The range of redness and swelling is usually small, with a diameter of 1-3 centimeters and a color of light red or pink. It usually appears within a few hours after administration, and some individuals' redness and swelling symptoms can disappear on their own within 1-2 days. However, there are also a few individuals whose redness and swelling lasts for a long time, up to 3-5 days.

Pain symptoms often accompany redness and swelling, and the degree of pain varies from person to person.

Local skin itching and rash

In addition to redness, swelling, and pain, local skin itching and rash are also possible local adverse reactions that it may cause. In related studies, about 15% -20% of experimental subjects experienced skin itching symptoms after administration, with itching mainly concentrated around the injection site. Some individuals may scratch due to itching, leading to skin damage and increasing the risk of infection. The manifestations of rash are diverse, commonly including papules, urticaria, etc. Spotted papules are mostly scattered red small papules with a diameter of about 1-2 millimeters, and some papules may merge into patches; Urticaria presents as a wheal like rash, with a light red or pale white color, varying in size and irregular shape. It usually appears within a few hours and can self resolve within a few hours to days, but is prone to recurrence. After analysis, this type of skin reaction may be a manifestation of allergic reactions.

Localized tissue hardening and necrosis (rare)

In rare cases, it may cause severe local adverse reactions such as local tissue hardening and necrosis. In current research cases, only a few experimental animals have experienced such situations. Local tissue induration is usually manifested as a hard mass with unclear boundaries at the injection site, which may be accompanied by pain when pressed. The resolution time of induration is relatively long, and some may take several weeks or even months. However, local tissue necrosis is even rarer. Once it occurs, it can lead to ischemia and hypoxia in the injection site tissue, resulting in necrosis. This is manifested as blackening of the local skin color, tissue ulceration, pus discharge, etc., which seriously affects the local tissue function. Moreover, the treatment is difficult and often requires debridement, and may even leave scars.

Neurological adverse reactions

Neurological adverse reactions are also one of the systemic adverse reactions that Slu-PP-332 Peptide may cause. Although the incidence is relatively low, the impact on the body cannot be ignored, mainly manifested as symptoms such as headache, dizziness, fatigue, and drowsiness. In rare cases, psychological symptoms such as insomnia, anxiety, and restlessness may occur. The incidence of headache symptoms in the experimental subjects is about 10% -15%. The headache site is mostly bilateral temples or forehead, and the nature of the pain is mostly swelling pain, dull pain or pulsating pain. The severity of the pain varies. Some individuals' headache symptoms may be relieved after rest, while a few individuals' headaches may last for a long time, affecting normal work and life.